Using generative AI, MIT researchers design compounds that can kill drug-resistant bacteria

AI used to design antibiotics that can combat drug-resistant superbugs gonorrhoea and MRSA

Antibiotics are used to kill bacteria, but some infections have become resistant to drugs. It is estimated drug-resistant bacterial infections cause nearly 5 million deaths per year worldwide.

AI-generated antibiotics have 'enormous potential' to combat superbugs if rolled out

Scientists at the Massachusetts Institute of Technology have used artificial intelligence to develop two promising antibiotics capable of combating drug-resistant strains of gonorrhoea and MRSA.The breakthrough research, published in the journal Cell, marks a significant advance in addressing antibiotic-resistant – or superbug – infections, which claim over one million lives annually.The innovative compounds were constructed atom-by-atom through…

Using generative AI, researchers design compounds that can kill drug-resistant bacteria

With help from artificial intelligence, MIT researchers designed novel antibiotics that can combat a drug-resistant form of Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA).

Generative AI models build new antibiotics starting from a single atom

Two lead compounds made by the model could kill multidrug-resistant gonorrhea and methicillin-resistant Staphylococcus aureus, or MRSA.

AI Creates New Antibiotics For Superbugs

Could artificial intelligence be the hero in our fight against superbugs?Researchers at MIT think so. They’ve just unveiled two brand-new antibiotic candidates — designed by AI, atom-by-atom. They wiped out drug-resistant gonorrhoea and MRSA in lab and animal tests.For decades, antibiotic discovery has stalled while bacteria have evolved deadly resistance, causing over a million deaths each year. “AI can enable us to come up with molecules cheap…

Generative AI designs compounds that can kill drug-resistant bacteria

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA).